Program
clesitamig
Also written as “ALPS12” and “RO7616789”.
Its studies are mostly in Small Cell Lung Carcinoma, led by Hoffmann-La Roche.
Furthest: phase 1, since Nov 9, 20222 company-led studies, 1 open or runningNext primary completion: Sep 30, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 21 open or running | phase 1since Nov 9, 2022 | Nov 9, 2022 | Sep 30, 2028phase 1 · NCT07107490 |
- Named in Hoffmann-La Roche’s own pipeline as
CHU clesitamig
, phase 1, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2022First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT05619744 · 41 enrolled · United States, Denmark, Japan and more
- Jul 30, 2025Phase 1 study in Extensive Stage Small Cell Lung CancerNCT07107490 · 122 planned · Hong Kong, Japan, Taiwan
Ahead
- Sep 30, 2028Primary completion: phase 1 study in Extensive Stage Small Cell Lung CancerNCT07107490
TargetBeta
“A trispecific T-cell engager antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), the T-cell costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), and the T-cell surface antigen CD3, with potential immunostimulatin…”NCIt, read by Claude
“A trispecific T-cell engager antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), the T-cell costimulatory receptor CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), and the T-cell surface antigen CD3, ”NCIt, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07107490Extensive Stage Small Cell Lung Cancer · Hong Kong, Japan, Taiwan | 1 | Recruiting | Sep 30, 2028 | 122 |
| NCT05619744Small Cell Lung Carcinoma · United States, Denmark, Japan and more | 1 | Completed | Mar 4, 2025 | 41 |
How it is read
Names in the registry
- “ALPS12”, 1 entry
- “RO7616789”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.